SynthesisInternational journal of colorectal disease2020

Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.

Cheng-Ann Winston Ng et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2020

Not counted

Probably reduced deaths

−40%−47% to −33%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.6, 95% CI 0.53–0.67 · the paper's word: All-cause mortality

Not counted

Probably reduced deaths

−34%−41% to −26%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.66, 95% CI 0.59–0.74 · the paper's word: All-cause mortality

Not counted

Probably reduced deaths

−23%−32% to −13%

Bigger than 7 in 10 for all-cause mortality

As reported

HR 0.77, 95% CI 0.68–0.87 · the paper's word: All-cause mortality

Three numbers in the abstract

the abstract, start to end

Overall survival (HR 0.6, CI 0.53-0.67, p < 0.001) and CRC-specific survival (HR 0.66, CI 0.59-0.74, p < 0.001) were …

… survival rates in metformin users (HR 0.77, CI 0.68-0.87, p < 0.001).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.60.53–0.67

All-cause mortality

HR 0.660.59–0.74

All-cause mortality

HR 0.770.68–0.87

MetforminAll-cause mortality

1 / 3

71 papers cite itlatest 60 shown

2020

…

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it

Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.

What the trial testedas reported · 2020

Probably reduced deaths

Probably reduced deaths

Probably reduced deaths

Three numbers in the abstract

Where each one falls

Where it lands on the map

71 papers cite itlatest 60 shown